PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.

Abstract The safety of active surveillance (AS) for Gleason 6 favorable intermediate-risk (FIR) prostate cancer is unknown. To provide guidance, we examined the incidence and predictors of upgrading or upstaging for Gleason 6 FIR patients treated with radical prostatectomy.
PMID
Related Publications

Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.

Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility.

Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.

The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.

Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.

Authors

Mayor MeshTerms
Keywords

Favorable intermediate-risk

Positive biopsy cores

Prostate-specific antigen

Upgrade

Upstage

Journal Title clinical genitourinary cancer
Publication Year Start




PMID- 29196209
OWN - NLM
STAT- Publisher
LR  - 20171202
IS  - 1938-0682 (Electronic)
IS  - 1558-7673 (Linking)
DP  - 2017 Nov 9
TI  - Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer
      Treated With Radical Prostatectomy: Implications for Active Surveillance.
LID - S1558-7673(17)30329-4 [pii]
LID - 10.1016/j.clgc.2017.10.013 [doi]
AB  - BACKGROUND: The safety of active surveillance (AS) for Gleason 6 favorable
      intermediate-risk (FIR) prostate cancer is unknown. To provide guidance, we
      examined the incidence and predictors of upgrading or upstaging for Gleason 6 FIR
      patients treated with radical prostatectomy. PATIENTS AND METHODS: We identified 
      2807 men in the National Cancer Database diagnosed from 2010 to 2012 with Gleason
      6 FIR disease (<50% positive biopsy cores [PBC] with either prostate-specific
      antigen [PSA] of 10-20 ng/mL or cT2b-T2c disease) treated with radical
      prostatectomy. Logistic regression was used to identify predictors of upgrading
      (Gleason 3+4 with tertiary Gleason 5 or Gleason >/=4+3) or upstaging (pT3-4/N1). 
      RESULTS: Fifty-seven percent of the cohort had PSA of 10 to 20 ng/mL; 25.5%
      patients with PSA of 10 to 20 ng/mL and 12.4% with cT2b to T2c disease were
      upgraded or upstaged. In multivariable analysis, predictors of upgrading or
      upstaging included increasing age (P = .026), PSA (P = .001), and percent PBC (P 
      < .001), and black race versus white (P = .035) for patients with PSA of 10 to 20
      ng/mL and increasing PSA (P = .001) and percent PBC (P < .001) for patients with 
      cT2b to T2c disease. Men with PSA of 15.0 to 20.0 ng/mL or 37.5% to 49.9% PBC
      with PSA of 10 to 20 ng/mL had >30% risk of upgrading or upstaging, whereas cT2b 
      to T2c patients with <12.5% PBC or PSA <5.0 ng/mL had <10% risk. CONCLUSION: We
      found that Gleason 6 FIR patients with cT2b to T2c tumors had a low risk of
      harboring higher grade or stage disease and would be reasonable AS candidates,
      whereas patients with PSA of 10 to 20 ng/mL had a high risk and might generally
      be poor AS candidates.
CI  - Copyright (c) 2017. Published by Elsevier Inc.
FAU - Yang, David D
AU  - Yang DD
AD  - Harvard Medical School, Boston, MA.
FAU - Mahal, Brandon A
AU  - Mahal BA
AD  - Harvard Radiation Oncology Program, Boston, MA.
FAU - Muralidhar, Vinayak
AU  - Muralidhar V
AD  - Harvard Radiation Oncology Program, Boston, MA.
FAU - Vastola, Marie E
AU  - Vastola ME
AD  - Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer
      Institute, Boston, MA.
FAU - Boldbaatar, Ninjin
AU  - Boldbaatar N
AD  - Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer
      Institute, Boston, MA.
FAU - Labe, Shelby A
AU  - Labe SA
AD  - Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer
      Institute, Boston, MA.
FAU - Nezolosky, Michelle D
AU  - Nezolosky MD
AD  - Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer
      Institute, Boston, MA.
FAU - Orio, Peter F 3rd
AU  - Orio PF 3rd
AD  - Harvard Medical School, Boston, MA; Department of Radiation Oncology, Brigham and
      Women's Hospital/Dana-Farber Cancer Institute, Boston, MA.
FAU - King, Martin T
AU  - King MT
AD  - Harvard Medical School, Boston, MA; Department of Radiation Oncology, Brigham and
      Women's Hospital/Dana-Farber Cancer Institute, Boston, MA.
FAU - Martin, Neil E
AU  - Martin NE
AD  - Harvard Medical School, Boston, MA; Department of Radiation Oncology, Brigham and
      Women's Hospital/Dana-Farber Cancer Institute, Boston, MA.
FAU - Mouw, Kent W
AU  - Mouw KW
AD  - Harvard Medical School, Boston, MA; Department of Radiation Oncology, Brigham and
      Women's Hospital/Dana-Farber Cancer Institute, Boston, MA.
FAU - Trinh, Quoc-Dien
AU  - Trinh QD
AD  - Harvard Medical School, Boston, MA; Division of Urological Surgery and Center for
      Surgery and Public Health, Brigham and Women's Hospital, Boston, MA.
FAU - Nguyen, Paul L
AU  - Nguyen PL
AD  - Harvard Medical School, Boston, MA; Department of Radiation Oncology, Brigham and
      Women's Hospital/Dana-Farber Cancer Institute, Boston, MA. Electronic address:
      [email protected]
LA  - eng
PT  - Journal Article
DEP - 20171109
PL  - United States
TA  - Clin Genitourin Cancer
JT  - Clinical genitourinary cancer
JID - 101260955
OTO - NOTNLM
OT  - Favorable intermediate-risk
OT  - Positive biopsy cores
OT  - Prostate-specific antigen
OT  - Upgrade
OT  - Upstage
EDAT- 2017/12/03 06:00
MHDA- 2017/12/03 06:00
CRDT- 2017/12/03 06:00
PHST- 2017/08/15 00:00 [received]
PHST- 2017/10/21 00:00 [revised]
PHST- 2017/10/30 00:00 [accepted]
PHST- 2017/12/03 06:00 [entrez]
PHST- 2017/12/03 06:00 [pubmed]
PHST- 2017/12/03 06:00 [medline]
AID - S1558-7673(17)30329-4 [pii]
AID - 10.1016/j.clgc.2017.10.013 [doi]
PST - aheadofprint
SO  - Clin Genitourin Cancer. 2017 Nov 9. pii: S1558-7673(17)30329-4. doi:
      10.1016/j.clgc.2017.10.013.